Literature DB >> 2953866

Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems.

M Ruberg, A Villageois, A M Bonnet, B Pillon, F Rieger, Y Agid.   

Abstract

Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) were assayed in the cerebrospinal fluid (CSF) of subjects with neurodegenerative diseases (dementing and non-dementing, with and without known cholinergic lesions), to determine whether CSF AChE is a valid marker of central cholinergic activity. The relative proportions of the different forms of each enzyme and of AChE to BChE were similar in CSF and brain. AChE decreased in Huntington's chorea (degeneration of striatal cholinergic interneurons) but also in multiple sclerosis (not known to affect cholinergic systems). BChE paralleled AChE, although the enzymes were dissociated in some patients. It is concluded that CSF AChE activity may globally reflect brain AChE, but pathology-induced changes may not be directly reflected.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2953866      PMCID: PMC1031964          DOI: 10.1136/jnnp.50.5.538

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  Central cholinergic-anticholinergic antagonism in Huntington's chorea.

Authors:  H L Klawans; R Rubovits
Journal:  Neurology       Date:  1972-02       Impact factor: 9.910

2.  Decreased ratio of CSF acetylcholinesterase to butyrylcholinesterase activity in Alzheimer's disease.

Authors:  T Arendt; V Bigl; F Walther; M Sonntag
Journal:  Lancet       Date:  1984-01-21       Impact factor: 79.321

3.  Decreased CSF acetylcholinesterase activity in Alzheimer's disease.

Authors:  M E Appleyard; A D Smith; G K Wilcock; M M Esiri
Journal:  Lancet       Date:  1983-08-20       Impact factor: 79.321

4.  Neurotransmitters and CNS disease. Dementia.

Authors:  M N Rossor
Journal:  Lancet       Date:  1982-11-27       Impact factor: 79.321

5.  The molecular forms of cholinesterase and acetylcholinesterase in vertebrates.

Authors:  J Massoulié; S Bon
Journal:  Annu Rev Neurosci       Date:  1982       Impact factor: 12.449

6.  Neurotransmitter-related enzymes in senile dementia of the Alzheimer type.

Authors:  P Davies
Journal:  Brain Res       Date:  1979-08-03       Impact factor: 3.252

7.  A subcortico-cortical cholinergic system is affected in Parkinson's disease.

Authors:  B Dubois; M Ruberg; F Javoy-Agid; A Ploska; Y Agid
Journal:  Brain Res       Date:  1983-12-12       Impact factor: 3.252

8.  Acetylcholinesterase activity in CSF in schizophrenia, depression, Alzheimer's disease and normals.

Authors:  S I Deutsch; R C Mohs; M I Levy; A B Rothpearl; D Stockton; T Horvath; A Coco; K L Davis
Journal:  Biol Psychiatry       Date:  1983-12       Impact factor: 13.382

9.  High dosage anticholinergic therapy in dystonia.

Authors:  S Fahn
Journal:  Neurology       Date:  1983-10       Impact factor: 9.910

10.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

Authors:  E K Perry; B E Tomlinson; G Blessed; K Bergmann; P H Gibson; R H Perry
Journal:  Br Med J       Date:  1978-11-25
View more
  10 in total

1.  Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis.

Authors:  L B Krupp; C Christodoulou; P Melville; W F Scherl; L-Y Pai; L R Muenz; D He; R H B Benedict; A Goodman; S Rizvi; S R Schwid; B Weinstock-Guttman; H J Westervelt; H Wishart
Journal:  Neurology       Date:  2011-04-26       Impact factor: 9.910

2.  Short-latency afferent inhibition predicts verbal memory performance in patients with multiple sclerosis.

Authors:  Laura Cucurachi; Paolo Immovilli; Franco Granella; Giovanni Pavesi; Luigi Cattaneo
Journal:  J Neurol       Date:  2008-10-07       Impact factor: 4.849

3.  Acetylcholine synthesis in human CSF: implications for study of central cholinergic metabolism.

Authors:  S T DeKosky; S W Scheff; C G Hackney
Journal:  Neurochem Res       Date:  1989-02       Impact factor: 3.996

4.  Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type.

Authors:  M E Appleyard; B McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

Review 5.  Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?

Authors:  Christopher Christodoulou; William S MacAllister; Nancy A McLinskey; Lauren B Krupp
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

6.  A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Authors:  Agneta Nordberg; Clive Ballard; Roger Bullock; Taher Darreh-Shori; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-07

7.  Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression.

Authors:  Nunzio Pomara; Davide Bruno; Chelsea Reichert Plaska; Anilkumar Pillai; Jaime Ramos-Cejudo; Ricardo Osorio; Bruno P Imbimbo; Amanda Heslegrave; Henrik Zetterberg; Kaj Blennow
Journal:  J Affect Disord       Date:  2021-03-09       Impact factor: 4.839

8.  Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis.

Authors:  Shahin Aeinehband; Rickard P F Lindblom; Faiez Al Nimer; Swetha Vijayaraghavan; Kerstin Sandholm; Mohsen Khademi; Tomas Olsson; Bo Nilsson; Kristina Nilsson Ekdahl; Taher Darreh-Shori; Fredrik Piehl
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

Review 9.  Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach.

Authors:  Karin D van Dijk; Charlotte E Teunissen; Benjamin Drukarch; Connie R Jimenez; Henk J Groenewegen; Henk W Berendse; Wilma D J van de Berg
Journal:  Neurobiol Dis       Date:  2010-05-06       Impact factor: 5.996

10.  Neuroprotective effect of nitric oxide donor isosorbide-dinitrate against oxidative stress induced by ethidium bromide in rat brain.

Authors:  Omar M E Abdel-Salam; Yasser Ashry Khadrawy; Nadia A Mohammed
Journal:  EXCLI J       Date:  2012-03-29       Impact factor: 4.068

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.